Aratana Therapeutics, Inc. Announces Pricing of Public Offering

KANSAS CITY, Kan., Sept. 17, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. PETX, a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced the pricing of its public offering of 4,500,000 shares of its common stock at a price to the public of $9.25 per share. Aratana has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock.

Jefferies LLC and Barclays are acting as joint book-running managers for the offering. 

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on July 15, 2014, which became effective on July 30, 2014.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A preliminary prospectus supplement describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, and when available, copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Jefferies LLC, c/o Equity Syndicate Prospectus Department, 520 Madison Avenue, 2^nd FL, New York, NY 10022, Prospectus_Department@Jefferies.com, (877) 547-6340; or Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, barclaysprospectus@broadridge.com, (888) 603-5847.

Contacts:

For investor inquires:
Aratana Therapeutics, Inc.

Craig Tooman
ctooman@aratana.com; (913) 353-1023

For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.